ENSC vs. MRNS, PMN, VRCA, SNYR, LEXX, AKTX, XLO, GDTC, BFRG, and JATT
Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Marinus Pharmaceuticals (MRNS), ProMIS Neurosciences (PMN), Verrica Pharmaceuticals (VRCA), Synergy CHC Corp. (Uplisting) (SNYR), Lexaria Bioscience (LEXX), Akari Therapeutics (AKTX), Xilio Therapeutics (XLO), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry.
Ensysce Biosciences vs.
Marinus Pharmaceuticals (NASDAQ:MRNS) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
Marinus Pharmaceuticals presently has a consensus price target of $4.79, suggesting a potential upside of 771.56%. Given Marinus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Marinus Pharmaceuticals is more favorable than Ensysce Biosciences.
In the previous week, Marinus Pharmaceuticals had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 1 mentions for Marinus Pharmaceuticals and 0 mentions for Ensysce Biosciences. Marinus Pharmaceuticals' average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.
Ensysce Biosciences has lower revenue, but higher earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.
Ensysce Biosciences has a net margin of -179.26% compared to Marinus Pharmaceuticals' net margin of -446.48%. Ensysce Biosciences' return on equity of -292.81% beat Marinus Pharmaceuticals' return on equity.
Marinus Pharmaceuticals has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Marinus Pharmaceuticals received 434 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 66.62% of users gave Marinus Pharmaceuticals an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote.
98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 5.5% of Marinus Pharmaceuticals shares are owned by company insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Marinus Pharmaceuticals beats Ensysce Biosciences on 12 of the 18 factors compared between the two stocks.
Get Ensysce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ensysce Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ENSC) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ENSC Stock Alerts